Domů › Mnohočetný myelom › Florida › Miami
Klinické studie Mnohočetný myelom v Miami, FL
21 studií pro Mnohočetný myelom hledá účastníky v lokalitách v Miami a okolí (do cca 30 mil). Otevřete studii a zjistěte, kdo se může zapojit a jak kontaktovat tým studie.
Oficiální text studie (anglicky)
Hledáte účastníky pro studii? Zvýrazněte ji nahoře na této stránce – $99 na 30 dní →
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Probíhá náborFáze 1/2
- University of Miami, Miami
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Probíhá náborFáze 2
- University of Miami Sylvester Comprehensive Cancer Center, Miami
- University of Miami/Sylvester Cancer Institute - Alex's Place, Miami
- University of Miami/Sylvester Cancer Institute - Griffin Cancer Research Building, Miami
- a dalších 2
ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0)
Probíhá náborFáze 2
- University of Miami, Miami
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Probíhá náborFáze 3
- University of Miami Hospital and Clinics, Sylvester Cancer Center, Miami
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Probíhá náborFáze 2
- Miami Cancer Institute at Baptist Health, Inc., Miami
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Probíhá náborFáze 3
- Sylvester Comprehensive Cancer Center, Miami
- University of Miami Hospital and Clinics - Griffin Cancer Research Building, Miami
- University of Miami Hospital and Clinics, Miami
- a dalších 3
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Probíhá náborFáze 3
- Sylvester Comprehensive Cancer Center, Miami
- University of Miami Hospital and Clinics, Miami
- Sylvester Comprehensive Cancer Center - Kendall, Miami
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
Probíhá náborFáze 2
- University of Miami, Miami
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Probíhá náborFáze 1
- University of Miami Don Soffer Clinical Research Center, Miami
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Probíhá náborFáze 1/2
- Research Site, Miami
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Probíhá náborFáze 1
- University of Miami, Miami
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
Probíhá náborFáze 4
- Sylvester Comprehensive Cancer Center, Miami
- University of Miami Hospital and Clinics - Griffin Cancer Research Building, Miami
- University of Miami Hospital and Clinics, Miami
FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease
Probíhá nábor
- University of Miami, Miami
Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions
Probíhá náborObservační studie
- University of Miami Hospitals, Miami
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Probíhá náborFáze 1/2
- University of Miami, Miami
- Miami Cancer Institute, Miami
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
Probíhá náborFáze 2
- University of Miami, Miami
Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)
Probíhá náborFáze 2
- University of Miami, Miami
Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
Probíhá náborFáze 2
- University of Miami, Sylvester Comprehensive Cancer Center, Miami
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Probíhá náborObservační studieVítáni zdraví dobrovolníci
- Miami Cancer Institute, Miami
Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse
Probíhá náborFáze 2
- University of Miami, Miami
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Probíhá náborFáze 1
- Sylvester Comprehensive Cancer Center, University of Miami Hospital and Clinics, Miami
Studie Mnohočetný myelom v jiných městech
- New York City, NY60 studií
- Boston, MA42 studií
- Atlanta, GA41 studií
- Houston, TX38 studií
- Durham, NC37 studií
- Nashville, TN32 studií
- Denver, CO27 studií
- Rochester, MN24 studií
- St. Louis, MO24 studií
- Columbus, OH24 studií
- Baldwin Park, CA23 studií
- Chicago, IL22 studií
Další studie v Miami
- Rakovina prsu42 studií
- Rakovina (všechny typy)36 studií
- Nemalobuněčný plicní karcinom31 studií
- Rakovina prostaty27 studií
- Obesity27 studií
- Akutní myeloidní leukemie24 studií
- Metastatický karcinom24 studií
- Rakovina vaječníků23 studií
- Nadváha23 studií
- Ulcerózní kolitida21 studií
- Alzheimerova choroba20 studií
- Rakovina plic20 studií
Zdroj: ClinicalTrials.gov, data načtena 3. 10. 2026. Každá studie má vlastní kritéria způsobilosti; o účasti rozhoduje tým studie.